ATHLONE, Ireland, March 13, 2015 (GLOBE NEWSWIRE) -- Innocoll AG (Nasdaq:INNL) (the “Company”), a global, commercial-stage, specialty pharmaceutical company that develops and manufactures a range of pharmaceutical products and medical devices using its proprietary collagen-based technologies, today announced that it will report fourth quarter and full year 2014 financial results before the open of U.S. financial markets on March 19, 2015. Innocoll management will host a webcast and conference call at 8:30 a.m. EDT that day to discuss the financial results and provide a corporate update.
The live call may be accessed by dialing 877-407-4018 for domestic callers and 201-689-8471 for international callers. A live webcast of the call will be available online from the investor relations section of the company website at www.innocollinc.com and will be archived there for 90 days. A telephone replay of the call will be available until midnight EDT on March 22, 2015 by dialing 877-870-5176 for domestic callers or 858-384-5517 for international callers and entering the conference code: 13601691.
About Innocoll AG
Innocoll is a global, commercial-stage, specialty pharmaceutical company. The Company develops and manufactures a range of pharmaceutical products and medical devices using its proprietary collagen-based technologies. The Company’s late stage product pipeline is focused on addressing a number of large unmet medical needs, including: XaraColl® for the treatment of post-operative pain; Cogenzia® for the adjuvant treatment of diabetic foot infections; and CollaGUARD®, a barrier for the prevention of post-surgical adhesions. The Company’s approved products include: CollaGUARD(Ex-US), Collatamp® G, Septocoll®, RegenePro®, Collieva®, CollaCare®, Collexa®, and Zorpreva™, which are sold through strategic partnerships with various partners including Takeda, Biomet, and Jazz Pharmaceuticals. All of the Company’s products are made using Type 1 collagen and are manufactured in-house at its facility in Saal, Germany. CollaRx®, Collatamp®, CollaGUARD®, Collieva®, CollaCare®, Collexa®, Cogenzia® LidoColl®, LiquiColl®, Septocoll®, and XaraColl® are registered trademarks, and CollaPress™, DermaSil™, Durieva™, and Zorpreva™ are trademarks of the Company.
CONTACT: Denise Carter Executive Vice President Business Development and Corporate Affairs T: (215) 765-0149 Investor Contact: Russo Partners, LLC Robert E. Flamm, Ph.D. (212) 845-4226 robert.flamm@russopartnersllc.com
Help employers find you! Check out all the jobs and post your resume.
